(HRTX) Heron Therapeuti - Ratings and Ratios
Anti-Nausea, Anesthetics, Injections
HRTX EPS (Earnings per Share)
HRTX Revenue
Description: HRTX Heron Therapeuti
Heron Therapeutics, Inc. is a commercial-stage biotechnology company that specializes in developing and commercializing therapeutics that enhance medical care. The companys proprietary Biochronomer technology enables the delivery of therapeutic levels of short-acting pharmacological agents over a prolonged period, ranging from days to weeks, with a single administration. This innovative technology is utilized in their product candidates, which are designed to address significant medical needs.
The companys product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for preventing nausea and vomiting associated with cancer chemotherapy. Additionally, Heron Therapeutics is developing ZYNRELEF, a dual-acting local anesthetic, and APONVIE, an intravenous formulation for preventing postoperative nausea and vomiting. These products have the potential to improve patient outcomes and enhance the quality of life for individuals undergoing chemotherapy and surgery.
From a technical analysis perspective, HRTXs stock price is currently at $2.11, with a 20-day simple moving average (SMA) of $2.16 and a 50-day SMA of $2.22, indicating a potential short-term downtrend. However, the 200-day SMA is $1.91, suggesting a longer-term uptrend. The average true range (ATR) is $0.17, representing an 8.24% volatility. Given the current technical indicators, it is likely that the stock price will experience a short-term correction before potentially resuming its longer-term uptrend.
Fundamentally, Heron Therapeutics has a market capitalization of $351.88M USD and a return on equity (RoE) of 22.24%, indicating a relatively strong financial performance. Although the company does not have a reported P/E ratio, its RoE suggests that it is generating significant profits. Considering the companys product pipeline, commercial-stage products, and financial performance, it is likely that HRTX will continue to experience growth in the coming quarters.
Based on the technical and fundamental analysis, a forecast for HRTX is as follows: the stock price is expected to experience a short-term correction, potentially down to $1.90-$2.00, before resuming its longer-term uptrend. In the next 6-12 months, the stock price is expected to reach $3.00-$3.50, driven by the companys continued growth and potential positive developments in its product pipeline. However, this forecast is subject to various risks and uncertainties, including market volatility and competition in the biotechnology industry.
Additional Sources for HRTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
HRTX Stock Overview
Market Cap in USD | 316m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 1987-08-26 |
HRTX Stock Ratings
Growth Rating | -67.0 |
Fundamental | 2.06 |
Dividend Rating | 0.0 |
Rel. Strength | -18.5 |
Analysts | 4.67 of 5 |
Fair Price Momentum | 1.56 USD |
Fair Price DCF | - |
HRTX Dividends
Currently no dividends paidHRTX Growth Ratios
Growth Correlation 3m | 20.4% |
Growth Correlation 12m | 4.6% |
Growth Correlation 5y | -83.8% |
CAGR 5y | -32.57% |
CAGR/Max DD 5y | -0.33 |
Sharpe Ratio 12m | -0.05 |
Alpha | -36.18 |
Beta | 0.679 |
Volatility | 84.19% |
Current Volume | 1054.1k |
Average Volume 20d | 1099.2k |
Stop Loss | 2.1 (-4.5%) |
As of July 09, 2025, the stock is trading at USD 2.20 with a total of 1,054,068 shares traded.
Over the past week, the price has changed by +1.38%, over one month by +3.77%, over three months by +24.29% and over the past year by -25.93%.
Neither. Based on ValueRay´s Fundamental Analyses, Heron Therapeuti is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 2.06 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HRTX is around 1.56 USD . This means that HRTX is currently overvalued and has a potential downside of -29.09%.
Heron Therapeuti has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy HRTX.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, HRTX Heron Therapeuti will be worth about 1.7 in July 2026. The stock is currently trading at 2.20. This means that the stock has a potential downside of -21.36%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 6.3 | 184.1% |
Analysts Target Price | 6.3 | 187.7% |
ValueRay Target Price | 1.7 | -21.4% |